REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.24−0.08 (-1.09%)
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Regenxbio r&d expenses
Research and development expenses are spending on new products and technology.
Regenxbio's R&D Expenses for the twelve months ending Jun 30, 2026 was $229.14M, up 5.4% year over year. For fiscal 2025 it was $228.30M, up 9.5% from the year before. Over ten years it grew 29.4% a year on average. The highest annual figure on record is $242.45M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $228.30M | +9.5% |
| FY2024 | Dec 31, 2024 | $208.52M | -10.2% |
| FY2023 | Dec 31, 2023 | $232.27M | -4.2% |
| FY2022 | Dec 31, 2022 | $242.45M | +33.6% |
| FY2021 | Dec 31, 2021 | $181.44M | +9.1% |
| FY2020 | Dec 31, 2020 | $166.29M | +33.9% |
| FY2019 | Dec 31, 2019 | $124.19M | +48.1% |
| FY2018 | Dec 31, 2018 | $83.87M | +46.6% |
| FY2017 | Dec 31, 2017 | $57.22M | +25.8% |
| FY2016 | Dec 31, 2016 | $45.48M | +163.2% |
| FY2015 | Dec 31, 2015 | $17.28M | +248.3% |
| FY2014 | Dec 31, 2014 | $4.96M | -1.8% |
| FY2013 | Dec 31, 2013 | $5.05M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $56.09M | -5.7% |
| Q1 FY2026 | Mar 31, 2026 | $57.34M | +8.0% |
| Q4 FY2025 | Dec 31, 2025 | $59.61M | +18.3% |
| Q3 FY2025 | Sep 30, 2025 | $56.10M | +3.1% |
| Q2 FY2025 | Jun 30, 2025 | $59.50M | +21.8% |
| Q1 FY2025 | Mar 31, 2025 | $53.09M | -3.2% |
| Q4 FY2024 | Dec 31, 2024 | $50.38M | -9.5% |
| Q3 FY2024 | Sep 30, 2024 | $54.43M | -6.5% |
| Q2 FY2024 | Jun 30, 2024 | $48.87M | -18.4% |
| Q1 FY2024 | Mar 31, 2024 | $54.84M | -6.3% |
| Q4 FY2023 | Dec 31, 2023 | $55.68M | -10.9% |
| Q3 FY2023 | Sep 30, 2023 | $58.18M | -8.1% |
| Q2 FY2023 | Jun 30, 2023 | $59.89M | -1.8% |
| Q1 FY2023 | Mar 31, 2023 | $58.52M | +5.2% |
| Q4 FY2022 | Dec 31, 2022 | $62.51M | +30.3% |
| Q3 FY2022 | Sep 30, 2022 | $63.31M | +32.3% |
| Q2 FY2022 | Jun 30, 2022 | $61.01M | +33.0% |
| Q1 FY2022 | Mar 31, 2022 | $55.63M | +40.0% |
| Q4 FY2021 | Dec 31, 2021 | $47.98M | +1.7% |
| Q3 FY2021 | Sep 30, 2021 | $47.86M | +8.8% |
| Q2 FY2021 | Jun 30, 2021 | $45.88M | +20.4% |
| Q1 FY2021 | Mar 31, 2021 | $39.72M | +7.3% |
| Q4 FY2020 | Dec 31, 2020 | $47.18M | +39.6% |
| Q3 FY2020 | Sep 30, 2020 | $43.97M | +23.2% |
| Q2 FY2020 | Jun 30, 2020 | $38.11M | +29.3% |
| Q1 FY2020 | Mar 31, 2020 | $37.04M | +46.9% |
| Q4 FY2019 | Dec 31, 2019 | $33.81M | +39.0% |
| Q3 FY2019 | Sep 30, 2019 | $35.69M | +92.8% |
| Q2 FY2019 | Jun 30, 2019 | $29.48M | +37.2% |
| Q1 FY2019 | Mar 31, 2019 | $25.20M | +28.9% |
| Q4 FY2018 | Dec 31, 2018 | $24.33M | +71.7% |
| Q3 FY2018 | Sep 30, 2018 | $18.51M | +47.9% |
| Q2 FY2018 | Jun 30, 2018 | $21.49M | +54.4% |
| Q1 FY2018 | Mar 31, 2018 | $19.55M | +17.6% |
| Q4 FY2017 | Dec 31, 2017 | $14.17M | -11.8% |
| Q3 FY2017 | Sep 30, 2017 | $12.52M | -0.3% |
| Q2 FY2017 | Jun 30, 2017 | $13.92M | – |
| Q1 FY2017 | Mar 31, 2017 | $16.62M | – |
| Q4 FY2016 | Dec 31, 2016 | $16.06M | – |
| Q3 FY2016 | Sep 30, 2016 | $12.56M | – |
See a number that looks wrong?